Olmesartan Medoxomilo Fantex (Olmesartan Medoxomil)

Olmesartan medoxomil is indicated for conditions involving elevated blood pressure within the renin‑angiotensin system.

• Essential hypertension: reduces systolic and diastolic blood pressure to target levels.
• Hypertension associated with diabetes: assists in achieving recommended blood pressure goals in diabetic patients.
• Hypertension in chronic kidney disease: helps control pressure to slow renal function decline.

• Olmesartan medoxomil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding and activating the receptor. This inhibition reduces vasoconstriction, aldosterone secretion, and sympathetic activation, leading to decreased peripheral vascular resistance and lower blood pressure.

Olmesartan medoxomil may cause a range of adverse reactions.

Common Side Effects

• Dizziness: feeling light‑headed, especially after standing.
• Headache: mild to moderate intensity.
• Fatigue: general tiredness or lack of energy.
• Abdominal pain: discomfort in the stomach area.
• Back pain: musculoskeletal discomfort.
• Nasal congestion: stuffy or runny nose.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or throat.
• Hyperkalemia: elevated potassium levels in blood.
• Acute kidney injury: sudden decline in renal function.
• Severe hypotension: markedly low blood pressure causing faintness.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Allergic reactions: rash, itching, or hives.

Before initiating therapy, consider the following safety measures.

• Blood pressure monitoring: regularly assess to ensure therapeutic effect.
• Renal function assessment: check serum creatinine and eGFR, especially in patients with existing kidney disease.
• Electrolyte surveillance: monitor potassium levels to avoid hyperkalemia.
• Pregnancy avoidance: do not use in pregnant women due to fetal risk.
• Elderly caution: start at lower dose and monitor for orthostatic hypotension.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxomil can interact with several drug classes.

Major Interactions (Avoid)

• Potassium‑sparing diuretics: may cause dangerous hyperkalemia.
• ACE inhibitors or other ARBs: combined use can lead to excessive blood pressure reduction and renal impairment.
• Lithium: increased lithium concentrations and toxicity risk.
• Aliskiren (in diabetics): heightened risk of hypotension, renal dysfunction, and hyperkalemia.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Diuretics: may require dose adjustment of olmesartan.
• Other antihypertensives: additive blood pressure lowering may necessitate careful titration.